2月11日,强生宣布旗下创新治疗药物锐珂(埃万妥单抗注射液)获得国家药品监督管理局批准,与卡铂和培美曲塞联合给药,用于经检测确认携带表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。强生方面认为,此次获批标志着强生在华正式进军肺癌治疗领域,有望重新定义治疗标准、开创肺癌治疗的新时代。进军国内肺癌治疗市场肺癌在我国所有恶性肿瘤中发病率和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.